UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 29, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
13-5315170
(State of Incorporation)
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.05 par value
PFE
New York Stock Exchange
0.250% Notes due 2022
PFE22
New York Stock Exchange
1.000% Notes due 2027
PFE27
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
At May 4, 2020, 5,554,833,754 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three months ended March 29, 2020 and March 31, 2019
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 29, 2020
and March 31, 2019
Condensed Consolidated Balance Sheets as of March 29, 2020 and December 31, 2019
Condensed Consolidated Statements of Equity for the three months ended March 29, 2020 and March 31, 2019
Condensed Consolidated Statements of Cash Flows for the three months ended March 29, 2020 and March 31, 2019
Notes to Condensed Consolidated Financial Statements
10
Review Report of Independent Registered Public Accounting Firm
42
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
43
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
85
Item 4.
Controls and Procedures
85
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
86
Item 1A.
Risk Factors
86
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
88
Item 3.
Defaults Upon Senior Securities
88
Item 4.
Mine Safety Disclosures
88
Item 5.
Other Information
88
Item 6.
Exhibits
89
Signature
90
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2019 Financial Report
Financial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019
2019 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2019
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
AML
Acute Myeloid Leukemia
Anacor
Anacor Pharmaceuticals, Inc.
Array
Array BioPharma Inc.
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
Bamboo
Bamboo Therapeutics, Inc.
BioNTech
BioNTech SE
Biopharma
Pfizer Biopharmaceuticals Group
BMS
Bristol-Myers Squibb Company
CDC
U.S. Centers for Disease Control and Prevention
cGMP
current Good Manufacturing Practices
CHMP
Committee for Medicinal Products for Human Use
COVID-19
novel coronavirus disease of 2019
Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and
New Zealand
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),
Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development organization
GSK
GlaxoSmithKline plc
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
IBT
Income before tax
ICU Medical
ICU Medical, Inc.
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson
JV
Joint Venture
King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDL
low density lipoprotein
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
MCO
managed care organization
mCRC
metastatic colorectal cancer
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation LLC (formerly Medivation, Inc.)
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
Mylan
Mylan N.V.
NDA
new drug application
NSCLC
non-small cell lung cancer
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
pharmacy benefit manager
Pharmacia
Pharmacia Corporation
PP&E
property, plant & equipment
PsA
psoriatic arthritis
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended March 29, 2020
RA
rheumatoid arthritis
RCC
renal cell carcinoma
R&D
research and development
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SI&A
selling, informational and administrative
S&P
Standard and Poor s
TCJA
legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Therachon
Therachon Holding AG
UC
ulcerative colitis
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
VBP
Volume-based procurement program
WRDM
Worldwide Research, Development and Medical
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
March 29,
2020
March 31,
2019
Revenues
12,028
13,118
Costs and expenses:
Cost of sales(a)
2,378
2,433
Selling, informational and administrative expenses(a)
2,873
3,339
Research and development expenses(a)
1,724
1,703
Amortization of intangible assets
885
1,183
Restructuring charges and certain acquisition-related costs
69
46
(Gain) on completion of Consumer Healthcare JV transaction
(6
Other (income)/deductions net
221
92
Income from continuing operations before provision for taxes on income
3,885
4,323
Provision for taxes on income
475
433
Income from continuing operations
3,410
3,889
Discontinued operations net of tax
Net income before allocation to noncontrolling interests
3,410
3,889
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
3,401
3,884
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.61
0.69
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.61
0.69
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.61
0.68
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.61
0.68
Weighted-average shares basic
5,545
5,635
Weighted-average shares diluted
5,613
5,750
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2020
March 31,
2019
Net income before allocation to noncontrolling interests
3,410
3,889
Foreign currency translation adjustments, net(a)
(1,272
324
Reclassification adjustments
(1,272
326
Unrealized holding gains/(losses) on derivative financial instruments, net
(501
267
Reclassification adjustments for (gains)/losses included in net income(b)
19
(263
(482
Unrealized holding gains/(losses) on available-for-sale securities, net
(51
40
Reclassification adjustments for losses included in net income(b)
15
11
(36
51
Benefit plans: actuarial losses, net
(166
Reclassification adjustments related to amortization
66
60
Reclassification adjustments related to settlements, net
53
Other
16
(23
(31
37
Reclassification adjustments related to amortization of prior service costs and other, net
(45
(46
Other
(1
(45
(46
Other comprehensive income/(loss), before tax
(1,867
372
Tax provision/(benefit) on other comprehensive income/(loss)
(377
25
Other comprehensive income/(loss) before allocation to noncontrolling interests
(1,490
348
Comprehensive income before allocation to noncontrolling interests
1,920
4,237
Less: Comprehensive income attributable to noncontrolling interests
Comprehensive income attributable to Pfizer Inc.
1,911
4,236
(a)
Amounts in the first quarter of 2020 include a loss of approximately $1.6 billion pre-tax ($1.2 billion after-tax) related to foreign currency translation adjustments attributable to our equity method investment in the GSK Consumer Healthcare joint venture (see Note 2B), partially offset by the results of our net investment hedging program.
(b)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
March 29,
2020
December 31,
2019
(Unaudited)
Assets
Cash and cash equivalents
2,151
1,305
Short-term investments
8,199
8,525
Trade accounts receivable, less allowance for doubtful accounts: 2020 $527; 2019 $527
9,881
8,724
Inventories
8,423
8,283
Current tax assets
3,346
3,344
Other current assets
2,737
2,622
Total current assets
34,738
32,803
Equity-method investments
15,524
17,133
Long-term investments
2,696
3,014
Property, plant and equipment, less accumulated depreciation: 2020 $16,929; 2019 $16,789
14,040
13,967
Identifiable intangible assets, less accumulated amortization
34,464
35,370
Goodwill
58,502
58,653
Noncurrent deferred tax assets and other noncurrent tax assets
2,207
2,099
Other noncurrent assets
4,166
4,450
Total assets
166,336
167,489
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2020 $337; 2019 $1,462
16,007
16,195
Trade accounts payable
3,972
4,220
Dividends payable
2,104
Income taxes payable
1,150
980
Accrued compensation and related items
2,246
2,720
Other current liabilities
10,515
11,083
Total current liabilities
33,890
37,304
Long-term debt
36,281
35,955
Pension benefit obligations, net
5,442
5,638
Postretirement benefit obligations, net
1,093
1,124
Noncurrent deferred tax liabilities
5,268
5,578
Other taxes payable
12,212
12,126
Other noncurrent liabilities
6,812
6,317
Total liabilities
100,998
104,042
Commitments and Contingencies
Preferred stock
17
17
Common stock
470
468
Additional paid-in capital
87,680
87,428
Treasury stock
(111,010
(110,801
Retained earnings
101,000
97,670
Accumulated other comprehensive loss
(13,131
(11,640
Total Pfizer Inc. shareholders equity
65,026
63,143
Equity attributable to noncontrolling interests
312
303
Total equity
65,338
63,447
Total liabilities and equity
166,336
167,489
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Preferred Stock
Common Stock
Treasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES)
Shares
Stated Value
Shares
Par Value
Add l
Paid-In Capital
Shares
Cost
Retained Earnings
Accum. Other Comp.
Loss
Share-
holders Equity
Non-controlling interests
Total Equity
Balance, January 1, 2020
431
17
9,369
468
87,428
(3,835
(110,801
97,670
(11,640
63,143
303
63,447
Net income
3,401
3,401
3,410
Other comprehensive income/(loss), net of tax
(1,490
(1,490
(1,490
Cash dividends declared:
Common stock
(71
(71
(71
Preferred stock
Noncontrolling interests
Share-based payment transactions
23
252
(6
(209
44
44
Purchases of common stock
Preferred stock conversions and redemptions
(14
(1
(1
(1
(1
Other
Balance, March 29, 2020
417
17
9,393
470
87,680
(3,841
(111,010
101,000
(13,131
65,026
312
65,338
PFIZER INC. SHAREHOLDERS
Preferred Stock
Common Stock
Treasury Stock
(MILLIONS, EXCEPT PREFERRED SHARES)
Shares
Stated Value
Shares
Par Value
Add l
Paid-In Capital
Shares
Cost
Retained Earnings
Accum. Other Comp.
Loss
Share-
holders Equity
Non-controlling interests
Total Equity
Balance, January 1, 2019
478
19
9,332
467
86,253
(3,615
(101,610
89,554
(11,275
63,407
351
63,758
Net income
3,884
3,884
3,889
Other comprehensive income/(loss), net of tax
353
353
(4
348
Cash dividends declared:
Common stock
(68
(68
(68
Preferred stock
Noncontrolling interests
Share-based payment transactions
26
383
(7
(306
78
78
Purchases of common stock
(180
(8,865
(8,865
(8,865
Preferred stock conversions and redemptions
(12
(1
(1
(1
Other(a)
19
19
19
Balance, March 31, 2019
466
19
9,358
468
86,635
(3,801
(110,781
93,388
(10,923
58,806
352
59,158
(a)
The increase to Retained earnings represents the cumulative effect of the adoption of a new accounting standard in the first quarter of 2019 for leases. For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2019 in our 2019 Financial Report.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
March 29,
2020
March 31,
2019
Operating Activities
Net income before allocation to noncontrolling interests
3,410
3,889
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
1,218
1,545
Asset write-offs and impairments
45
155
TCJA impact(a)
(131
Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed
(6
Deferred taxes from continuing operations
109
(60
Share-based compensation expense
64
185
Benefit plan contributions in excess of expense/income
(248
(151
Other adjustments, net
123
(236
Other changes in assets and liabilities, net of acquisitions and divestitures
(1,581
(3,498
Net cash provided by operating activities
3,133
1,698
Investing Activities
Purchases of property, plant and equipment
(463
(460
Purchases of short-term investments
(2,551
(1,402
Proceeds from redemptions/sales of short-term investments
3,257
3,601
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less